Target intelligence / Profile preview

Bacterial 23S ribosomal RNA (23S rRNA)

Target
23S rRNA
Molecular classification
Ribosomal RNA, Nucleic acid, Other
01

Overview

Bacterial 23S ribosomal RNA (23S rRNA) is a key catalytic and structural component of the large (50S) subunit of the bacterial ribosome. It plays a fundamental role in protein synthesis by forming the peptidyl transferase center (PTC), which catalyzes peptide bond formation during translation elongation, and by shaping the nascent peptide exit tunnel (NPET) through which newly synthesized polypeptide chains leave the ribosome. Because of its essential role in bacterial viability and its structural divergence from eukaryotic cytoplasmic ribosomes, 23S rRNA is a highly successful target for several classes of clinically important antibiotics, including macrolides, lincosamides, streptogramins, oxazolidinones, and pleuromutilins. These drugs bind to specific sites on the 23S rRNA, such as the PTC or the NPET, to physically block translation or peptide bond formation, leading to bacterial cell death or growth inhibition. However, the clinical utility of these agents is increasingly threatened by resistance mechanisms, such as target site mutations (e.g., A2058G) or enzymatic methylation of the rRNA by Erm methyltransferases. Additionally, off-target binding to human mitochondrial ribosomes, which share structural homology with bacterial ribosomes, can lead to significant toxicities such as myelosuppression and lactic acidosis.

Other names
23S ribosomal RNABacterial 23S rRNA50S ribosomal subunit 23S rRNAPeptidyl transferase center RNANascent peptide exit tunnel RNA
02

Mechanism of action

Inhibition of bacterial protein synthesis by binding to the 23S rRNA of the 50S ribosomal subunit, blocking peptidyl transferase activity or sterically obstructing the nascent peptide exit tunnel.

03

Biological functions

Protein synthesisTranslationPeptidyl transferase activityOther
04

Disease associations

Infection
05

Safety considerations

Mitochondrial toxicity (due to structural similarity with human mitochondrial 16S rRNA, leading to myelosuppression, lactic acidosis, and neuropathies)Antimicrobial resistanceGastrointestinal distress (e.g., motilin receptor agonism by macrolides)QT interval prolongationDrug-drug interactions (e.g., CYP3A4 inhibition)
06

Interacting drugs

9 more in the full profile.

07

Biomarkers

23S rRNA gene mutations (e.g., A2058G, A2059G, G2576T)erm genes (e.g., ermA, ermB, ermC)mef genes (e.g., mefA)cfr geneMinimum Inhibitory Concentration (MIC)

Beyond the preview

Go deeper on Bacterial 23S ribosomal RNA (23S rRNA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bacterial 23S ribosomal RNA (23S rRNA).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call